ITK

Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Retrieved on: 
Tuesday, April 9, 2024
ITK, Atopic dermatitis, Patient, Disease, Cytokine

BURLINGAME, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced the initiation of the Company’s randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. The trial is expected to enroll 64 patients at 12 sites in the United States, with the potential for initial clinical data before year-end 2024.

Key Points: 
  • Atopic dermatitis is the first immune disease indication being studied in the clinic for soquelitinib, the Company’s selective ITK inhibitor
    BURLINGAME, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced the initiation of the Company’s randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis.
  • The trial is expected to enroll 64 patients at 12 sites in the United States, with the potential for initial clinical data before year-end 2024.
  • “The initiation of our Phase 1 atopic dermatitis trial is an important step towards unlocking the broad potential of ITK inhibition for immune diseases,” said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus.
  • In addition, the Company has evaluated soquelitinib in companion dogs with naturally occurring, refractory atopic dermatitis.

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, March 19, 2024
Atopic dermatitis, Head, T helper cell, HNSCC, Patient, PTCL, Lung cancer, Ipilimumab, Asthma, CTCL, ALCL, Fungal infection, Pulmonary fibrosis, Lymphocyte, RCC, Clinical trial, CRS, Marketing, B-cell lymphoma, Research, PR, PTCL-NOS, Psoriasis, T-cell lymphoma, ASH, Webcast, Immunomodulation, Pembrolizumab, PRS, Exposition, Cancer, Nivolumab, Safety, Scleroderma, Food, NSCLC, Teva Pharmaceuticals, Modified, Lymphoma, Knowledge, Allergy, Immunodeficiency, Time management, Peripheral, Poster, FDA, ITK, Conference call, Kidney cancer, T helper 17 cell, Society, Preprint, BioRxiv, Autoimmunity, Physician, Total, Pharmaceutical industry

BURLINGAME, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • ET / 1:30 p.m. PT
    BURLINGAME, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2023.
  • We have several exciting opportunities in immunology, including plans for a randomized, placebo controlled clinical trial of soquelitinib in atopic dermatitis.
  • Mr. Arcara previously served as senior vice president, head global marketing & portfolio and strategy for the innovative medicines and biosimilars business at Teva Pharmaceuticals.
  • ET (1:30 p.m. PT), during which time management will provide a business update and discuss the fourth quarter and full year 2023 financial results.

Veeam to Jointly Develop AI Solutions with Microsoft for Industry’s #1 Data Protection and Ransomware Recovery Platform

Retrieved on: 
Thursday, March 7, 2024
Data Management, Technology, Security, Other Technology, Telecommunications, Apps, Applications, Software, Artificial Intelligence, Networks, Internet, Mobile, Wireless, Cloud, Information privacy, TCO, AI, ITK, Investment, Microsoft Azure, First officer (aviation), Data, Piraeus Bank, Face, Software as a service, Organization, As a service, Infrastructure as a service, Platform as a service, VMS, Data analysis, Cloud computing, Backup, Microsoft, Environment, Partnership, Video game

In addition to joint innovation, the companies will bring to market data protection for Microsoft 365 and Microsoft Azure with the recently announced Veeam Data Cloud .

Key Points: 
  • In addition to joint innovation, the companies will bring to market data protection for Microsoft 365 and Microsoft Azure with the recently announced Veeam Data Cloud .
  • Veeam’s solution for Microsoft 365 data protection provides the fastest data restores available.
  • Extending our partnership with Microsoft brings the benefits of Veeam technology – in both data protection and ransomware recovery – to even more customers using Microsoft 365 and Microsoft Azure.
  • “Together with Veeam, we are already helping millions of users fully protect their business data across Microsoft 365 and Microsoft Azure.

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases

Retrieved on: 
Monday, February 12, 2024
Atopic dermatitis, Immunodeficiency, Psoriasis, Infection, SQL, ITK, Scleroderma, Preprint, Asthma, T helper cell, Pulmonary fibrosis, T helper 17 cell, Venn, Lymphocyte, Cytokine, Rheumatoid arthritis, Immunosuppression, Dermatitis, Publication, Lymphoma, Research, Immunomodulation, Vaccine

BURLINGAME, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that preclinical data for soquelitinib, the Company’s lead ITK inhibitor program, was presented in a poster session at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases, which took place February 8-11, 2024.

Key Points: 
  • BURLINGAME, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that preclinical data for soquelitinib, the Company’s lead ITK inhibitor program, was presented in a poster session at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases, which took place February 8-11, 2024.
  • These preclinical product candidates exhibit specific biologic properties that are anticipated to enable more precise inhibition of Th1, Th2 and/or Th17 cell function.
  • Atopic dermatitis (also called eczema) and asthma are thought to be mediated primarily by Th2 lymphocytes.
  • The soquelitinib preclinical data and information on the Company’s next-generation ITK inhibitor candidates was presented by Rahul Pawar, Ph.D., Senior Scientist at Corvus, in poster session #2 (poster #2008) at the Keystone Symposia.

Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma

Retrieved on: 
Thursday, February 8, 2024
Lymphoma, Food, T-cell lymphoma, PTCL, ITK, Toxicity, Patient, FDA, Pharmaceutical industry

BURLINGAME, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for soquelitinib for the treatment of T cell lymphoma.

Key Points: 
  • BURLINGAME, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for soquelitinib for the treatment of T cell lymphoma.
  • Soquelitinib, the Company’s lead ITK inhibitor candidate, is expected to advance into a Phase 3 registrational clinical trial in patients with relapsed peripheral T cell lymphoma (PTCL) in the second quarter 2024.
  • “Peripheral T cell lymphoma is an aggressive subset of non-Hodgkin’s lymphoma typically associated with a poor prognosis,” said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus.
  • The orphan drug designation is an important milestone in the development of soquelitinib that reinforces the unmet need for patients with T cell lymphoma.”
    FDA Orphan Drug Designation is granted to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the United States.

Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer

Retrieved on: 
Tuesday, February 6, 2024
Janssen Pharmaceuticals, Marketing, Abbott Laboratories, Patient, Teva Pharmaceuticals, ITK, MBA, Management, Laboratory, University, University of Wisconsin–Madison

BURLINGAME, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced the appointment of Jeffrey Arcara as Chief Business Officer.

Key Points: 
  • BURLINGAME, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced the appointment of Jeffrey Arcara as Chief Business Officer.
  • “Corvus is leading the development of ITK inhibition as a platform opportunity across oncology and immune diseases.
  • The addition of Jeff as chief business officer strengthens our ability to maximize the potential of our ITK programs, both internally and through partnerships.
  • I look forward to leveraging my industry experience, including in oncology and immunology, to help drive the success of Corvus’ pipeline,” said Mr. Arcara.

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023
Allergy, Neoplasm, FDA, Research, Psoriasis, Kidney cancer, NSCLC, Scientific Reports, Carcinoma, Pulmonary fibrosis, Nivolumab, Asilomar International Conference on Climate Intervention Technologies, T helper cell, Preprint, Scleroderma, PTCL, Pembrolizumab, Head, 65th Infantry Regiment, BioRxiv, Cytokine, Time management, Ipilimumab, RCC, ITK, Society, ASH, Clinical trial, Science, Asthma, Cancer, Webcast, Lung cancer, Autoimmunity, Total, Conference call, Patient, Lymphoma, Communications satellite, Pharmaceutical industry, Vaccine, Cryptocurrency, T helper 17 cell, Corvus, Conference

BURLINGAME, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • ET / 1:30 p.m. PT
    BURLINGAME, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the third quarter ended September 30, 2023.
  • The latest data from the trial was reported at the International Conference on Malignant Lymphoma, which took place June 13-17, 2023 in Lugano, Switzerland.
  • The paper highlights the potential of selective ITK inhibition for the treatment of cancers and helps to confirm preclinical and clinical results generated by Corvus.
  • ET (1:30 p.m. PT), during which time management will provide a business update and discuss the third quarter 2023 financial results.

MÉTIS NATIONAL COUNCIL SUPPORTS INUIT TAPIRIIT KANATAMI’S ALERT ON FALSE IDENTITY

Retrieved on: 
Tuesday, November 7, 2023
National Council, Akaitcho Territory Government, NCC, Registry, Human, Cassidy, Organization, Indigenous self-government in Canada, NunatuKavut, ITK, Labrador, First Nations, MNC, Partnership, Community council, Provincial, Federal, Culture, Whaling, Drug

As stated by ITK in their Open Letter from Inuit Tapiriit Kanatami to Alert Canadians to False Claims to Inuit Identity, prior to its claims to Inuit identity, the NCC called itself the Labrador Métis Nation.

Key Points: 
  • As stated by ITK in their Open Letter from Inuit Tapiriit Kanatami to Alert Canadians to False Claims to Inuit Identity, prior to its claims to Inuit identity, the NCC called itself the Labrador Métis Nation.
  • The Métis National Council takes these false claims of Indigenous identity very seriously.
  • The MNC and our Governing Members will continue to take action to protect the Métis Nation from false claims of Indigenous identity and to protect the territorial integrity of the historic Métis Nation.
  • Cassidy Caron is the President of the Métis National Council.

Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Monday, November 6, 2023
Janus, Research, Lilly, Eli Lilly and Company, AD, Plasma, Half-life, PD, Psoriatic arthritis, Washington University in St. Louis, Biomarker, JAK3, EPI, G&A, Health, Rheumatoid arthritis, MAD, JAK, R, RA, ITK, ACRS, Ulcerative colitis, Osteoporosis, Pharmacokinetics, Hidradenitis suppurativa, PK, Methotrexate, Pancreatic cancer, Safety, Atopic dermatitis, Collection, Chapter 11, Title 11, United States Code, Therapy, Patient, MK2, Pharmaceutical industry, Vaccine, Palladium, Cryptocurrency, Rare-earth element, Tobacco, Hydraulic machinery

WAYNE, Pa., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the third quarter of 2023 and provided a corporate update.

Key Points: 
  • Net loss was $29.3 million for the third quarter of 2023 compared to $20.0 million for the third quarter of 2022.
  • Total revenue was $9.3 million for the third quarter of 2023 compared to $19.0 million for the third quarter of 2022.
  • Research and development (R&D) expenses were $23.9 million for the quarter ended September 30, 2023 compared to $23.7 million for the prior year period.
  • General and administrative (G&A) expenses were $7.1 million for the quarter ended September 30, 2023 compared to $5.8 million for the corresponding prior year period.

Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases

Retrieved on: 
Wednesday, November 1, 2023
T helper 17 cell, Psoriasis, Medical research, Pulmonary fibrosis, Publication, Scleroderma, Preprint, Immunodeficiency, TGF, RNA, Cytokine, Fibrosis, GVHD, Research, Inflammation, INSERM, ITK, Induction, MMP2, Hôpital Cochin, Systemic, Clinical trial, Asthma, Atopic dermatitis, Cancer, IL-5, Memorial Sloan Kettering Cancer Center, Lymphoma, Chronic obstructive pulmonary disease, COPD, Enteropathy-associated T-cell lymphoma, Lupus, Extractive metallurgy, Vaccine, Rheumatology, Corvus, T helper cell

BURLINGAME, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the publication of preclinical data that demonstrated the potential of ITK inhibition as a novel approach to treat T cell-mediated inflammatory and immune diseases. Corvus’ ITK inhibitors include soquelitinib (formerly known as CPI-818), which was used in the preclinical studies and is currently in clinical trials for oncology indications, and several next-generation molecules that are being optimized for use in a variety of inflammatory and immune disease indications.

Key Points: 
  • “Our research on soquelitinib and selective ITK inhibition is uncovering valuable new information about immune function and the role of ITK in different diseases,” said James Rosenbaum, M.D., senior vice president of research at Corvus.
  • “The activity of soquelitinib in various inflammatory and immune disease models highlights the essential role of ITK in multiple T cell functions.
  • The publication is now available online as a preprint at bioRxiv.org and on the Publications and Presentations page of the Corvus website.
  • With this new publication, we further demonstrate the wide range of opportunities for ITK inhibition across specific indications with ongoing patient needs for new therapies.